List of COVID-19 ARB trials

Adding COVID MED Trial info

philipn authored on Oct. 19, 2020, 7:25 p.m.

Medication info, via clinicaltrials.gov

Review changes View this version of the page

You can also use the and keys

~~Deletions are marked like this~~	Additions are marked like this
The first randomized controlled trial of an ARB for treatment of COVID-19 returned preliminary results showing possible improvements in time to discharge, need for supplementary oxygen and CRP. See "Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report." List of Angiotensin-receptor blocker (ARB) trials for COVID-19: Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection. Intervention: Losartan 12.5mg bid, can be increased based on SBP. Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease. Intervention: Valsartan titrated based on BP, maximum of 160mg bid. COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 (COVIDMED). Intervention: Losartan, not specified. Study of Open Label Losartan in COVID-19. Intervention: Losartan 20mg qd, escalated to 50mg od. Losartan for Patients With COVID-19 Requiring Hospitalization. Intervention: Losartan 50mg od. Losartan for Patients With COVID-19 Not Requiring Hospitalization. Intervention: Losartan 25mg od. Coronavirus Response - Active Support for Hospitalised Covid-19 Patients (CRASH-19). Intervention: Losartan 100mg od. Telmisartan for Treatment of COVID-19 Patients. Intervention: Telmisartan 80mg bid. Results: Preliminary results Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19) (COVERAGE). Intervention: Telmisartan 20mg od. Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease (CLARITY). Intervention: ARB, dose/medication not specified. Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia. Intervention: Losartan 25mg bid. Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection (TITAN). Intervention: Losartan 50mg od. Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) (ACOVACT). Intervention: Candesartan 4mg od, titrated up based on BP. Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients. Intervention: Telmisartan 40mg od. Host Response Mediators in Coronavirus (COVID-19) Infection (ARBS CORONA I). Intervention: observational study of existing ACEi/ARB users. Host response mediators in Coronavirus (COVID-19) infection - Is there a protective effect of ARBs on outcomes of Coronavirus infection? (ARBs CORONA II). Intervention: Losartan, dose/frequency not stated. News article on trial. The McGill RAAS-COVID-19 Randomized Controlled Trial (RAAS-COVID). Intervention: observational study of existing ACEi/ARB users. Will suspend or hold ACEi/ARB. Telmisartan in Respiratory Failure Due to COVID-19 (STAR-COVID). Intervention: Telmisartan 40mg od. Evaluation of the effects of Losartan in patients with corona virus disease 2019. Intervention: Losartan 25mg bid. ACE inhibitor trials: Ramipril for the Treatment of COVID-19 (RAMIC). Intervention: Ramipril 2.5 od. Other trials of renin-angiotensin modulation for COVID-19: BRACE CORONA, a randomized controlled trial exploring stopping-versus-continuing ACE inhibitors/ARBs in patients with hypertension, showed no harm in continuation of ACE inhibitors and ARBs with COVID-19. There was a non-statistically significant hint of a benefit in the ACEi/ARB group but the trial was not powered to detect this. Treatment of Angiotensin Peptide (1-7) for COVID-19 Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial (ATCO) TXA COVID-19 Clinical Trial RAS and Coagulopathy in COVID19 See also COVID-19 therapeutics	The first randomized controlled trial of an ARB for treatment of COVID-19 returned preliminary results showing possible improvements in time to discharge, need for supplementary oxygen and CRP. See "Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report." List of Angiotensin-receptor blocker (ARB) trials for COVID-19: Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection. Intervention: Losartan 12.5mg bid, can be increased based on SBP. Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease. Intervention: Valsartan titrated based on BP, maximum of 160mg bid. COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 (COVIDMED). Intervention: Losartan, 25 mg po QD X 5-14 days "depending on availability." Study of Open Label Losartan in COVID-19. Intervention: Losartan 20mg qd, escalated to 50mg od. Losartan for Patients With COVID-19 Requiring Hospitalization. Intervention: Losartan 50mg od. Losartan for Patients With COVID-19 Not Requiring Hospitalization. Intervention: Losartan 25mg od. Coronavirus Response - Active Support for Hospitalised Covid-19 Patients (CRASH-19). Intervention: Losartan 100mg od. Telmisartan for Treatment of COVID-19 Patients. Intervention: Telmisartan 80mg bid. Results: Preliminary results Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19) (COVERAGE). Intervention: Telmisartan 20mg od. Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease (CLARITY). Intervention: ARB, dose/medication not specified. Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia. Intervention: Losartan 25mg bid. Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection (TITAN). Intervention: Losartan 50mg od. Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) (ACOVACT). Intervention: Candesartan 4mg od, titrated up based on BP. Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients. Intervention: Telmisartan 40mg od. Host Response Mediators in Coronavirus (COVID-19) Infection (ARBS CORONA I). Intervention: observational study of existing ACEi/ARB users. Host response mediators in Coronavirus (COVID-19) infection - Is there a protective effect of ARBs on outcomes of Coronavirus infection? (ARBs CORONA II). Intervention: Losartan, dose/frequency not stated. News article on trial. The McGill RAAS-COVID-19 Randomized Controlled Trial (RAAS-COVID). Intervention: observational study of existing ACEi/ARB users. Will suspend or hold ACEi/ARB. Telmisartan in Respiratory Failure Due to COVID-19 (STAR-COVID). Intervention: Telmisartan 40mg od. Evaluation of the effects of Losartan in patients with corona virus disease 2019. Intervention: Losartan 25mg bid. ACE inhibitor trials: Ramipril for the Treatment of COVID-19 (RAMIC). Intervention: Ramipril 2.5 od. Other trials of renin-angiotensin modulation for COVID-19: BRACE CORONA, a randomized controlled trial exploring stopping-versus-continuing ACE inhibitors/ARBs in patients with hypertension, showed no harm in continuation of ACE inhibitors and ARBs with COVID-19. There was a non-statistically significant hint of a benefit in the ACEi/ARB group but the trial was not powered to detect this. Treatment of Angiotensin Peptide (1-7) for COVID-19 Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial (ATCO) TXA COVID-19 Clinical Trial RAS and Coagulopathy in COVID19 See also COVID-19 therapeutics

~~Deletions are marked like this~~

Additions are marked like this

The first randomized controlled trial of an ARB for treatment of COVID-19 returned preliminary results showing possible improvements in time to discharge, need for supplementary oxygen and CRP. See "Telmisartan for treatment of Covid-19 patients: an open randomized clinical trial. Preliminary report."

List of Angiotensin-receptor blocker (ARB) trials for COVID-19:

Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection. Intervention: Losartan 12.5mg bid, can be increased based on SBP.
Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease. Intervention: Valsartan titrated based on BP, maximum of 160mg bid.
COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 (COVIDMED). Intervention: Losartan, not specified.
Study of Open Label Losartan in COVID-19. Intervention: Losartan 20mg qd, escalated to 50mg od.
Losartan for Patients With COVID-19 Requiring Hospitalization. Intervention: Losartan 50mg od.
Losartan for Patients With COVID-19 Not Requiring Hospitalization. Intervention: Losartan 25mg od.
Coronavirus Response - Active Support for Hospitalised Covid-19 Patients (CRASH-19). Intervention: Losartan 100mg od.
Telmisartan for Treatment of COVID-19 Patients. Intervention: Telmisartan 80mg bid.
- Results: Preliminary results
Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19) (COVERAGE). Intervention: Telmisartan 20mg od.
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease (CLARITY). Intervention: ARB, dose/medication not specified.
Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia. Intervention: Losartan 25mg bid.
Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection (TITAN). Intervention: Losartan 50mg od.
Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) (ACOVACT). Intervention: Candesartan 4mg od, titrated up based on BP.
Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients. Intervention: Telmisartan 40mg od.
Host Response Mediators in Coronavirus (COVID-19) Infection (ARBS CORONA I). Intervention: observational study of existing ACEi/ARB users.
Host response mediators in Coronavirus (COVID-19) infection - Is there a protective effect of ARBs on outcomes of Coronavirus infection? (ARBs CORONA II). Intervention: Losartan, dose/frequency not stated.
- News article on trial.
The McGill RAAS-COVID-19 Randomized Controlled Trial (RAAS-COVID). Intervention: observational study of existing ACEi/ARB users. Will suspend or hold ACEi/ARB.
Telmisartan in Respiratory Failure Due to COVID-19 (STAR-COVID). Intervention: Telmisartan 40mg od.
Evaluation of the effects of Losartan in patients with corona virus disease 2019. Intervention: Losartan 25mg bid.

ACE inhibitor trials:

Ramipril for the Treatment of COVID-19 (RAMIC). Intervention: Ramipril 2.5 od.

Other trials of renin-angiotensin modulation for COVID-19:

BRACE CORONA, a randomized controlled trial exploring stopping-versus-continuing ACE inhibitors/ARBs in patients with hypertension, showed no harm in continuation of ACE inhibitors and ARBs with COVID-19. There was a non-statistically significant hint of a benefit in the ACEi/ARB group but the trial was not powered to detect this.

philipn / List of COVID-19 ARB trials 357e67c5f7abb1c036c2df1e49449bb37ae530ec

ACE inhibitor trials:

Other trials of renin-angiotensin modulation for COVID-19:

See also

ACE inhibitor trials:

Other trials of renin-angiotensin modulation for COVID-19:

See also